$AMGN · Amgen Inc.
Amgen Inc. filed a Form 4 with the SEC reporting a change in beneficial ownership by David W. Gibbs, a director of the company. The filing states that on November 6, 2026, Gibbs acquired 278 shares of Amgen common stock at a price of $0. Following the transaction, he directly held 278 shares.
The shares were issued in connection with restricted stock units granted under the Amgen Inc. 2009 Director Equity Incentive Program, as amended, under the company’s Second Amended and Restated 2009 Equity Incentive Plan. The restricted stock units vested immediately and are paid in shares of common stock on a one-to-one basis. Vested units may be deferred by the director, in which case payment would occur according to an elected deferral schedule.
The filing was signed on November 9, 2026, by an attorney-in-fact on behalf of Gibbs.